EA200900804A1 - MEANS ACTIVATING SEXUAL FUNCTION - Google Patents

MEANS ACTIVATING SEXUAL FUNCTION

Info

Publication number
EA200900804A1
EA200900804A1 EA200900804A EA200900804A EA200900804A1 EA 200900804 A1 EA200900804 A1 EA 200900804A1 EA 200900804 A EA200900804 A EA 200900804A EA 200900804 A EA200900804 A EA 200900804A EA 200900804 A1 EA200900804 A1 EA 200900804A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sexual function
heptapeptide
pro
rat
noted
Prior art date
Application number
EA200900804A
Other languages
Russian (ru)
Other versions
EA013948B1 (en
Inventor
Антон Иосифович ОРЛОВ
Петр Дмитриевич Шабанов
Сергей Борисович СЕРЕДЕНИН
Original Assignee
Общество С Ограниченной Ответственностью "Витанта"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Витанта" filed Critical Общество С Ограниченной Ответственностью "Витанта"
Priority to EA200900804A priority Critical patent/EA200900804A1/en
Publication of EA013948B1 publication Critical patent/EA013948B1/en
Publication of EA200900804A1 publication Critical patent/EA200900804A1/en

Links

Abstract

Изобретение относится к гептапептиду (Thr-Lyz-Pro-Arg-Pro-Gly-Pro), применяемому в качестве средства, активирующего половую функцию. Показано в опытах на крысах самцах, что однократная (100 мкг/крысу) или трехкратная (3 раза по 100 мкг/крысу) инъекция гептапептида вызывала активацию центральных пусковых механизмов половой функции, что проявлялось значительным (более чем 3-кратным) сокращением времени латентности садок и интромиссий. Общее структурное усиление половой функции отмечали на 7-й день после последней инъекции гептапептида (отсроченный эффект). Увеличивалось также число эякуляций при сокращении ее временных характеристик. Препарат сравнения (экстракт горца птичьего) проявлял более слабую стимулирующую половую функцию активность и не проявлял эффекта последействия, отмеченного для гептапептида.The invention relates to heptapeptide (Thr-Lyz-Pro-Arg-Pro-Gly-Pro), used as a means of activating sexual function. It was shown in experiments on male rats that a single (100 μg / rat) or three times (3 times 100 μg / rat) heptapeptide injection caused the activation of the central triggers of sexual function, which was manifested by a significant (more than 3-fold) reduction of the cage and intromissy. General structural enhancement of sexual function was noted on the 7th day after the last injection of heptapeptide (delayed effect). The number of ejaculations also increased while reducing its temporal characteristics. The comparator drug (poultry mountaineer extract) showed a weaker stimulatory sexual function and did not show the effect of the aftereffect noted for heptapeptide.

EA200900804A 2009-06-08 2009-06-08 MEANS ACTIVATING SEXUAL FUNCTION EA200900804A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200900804A EA200900804A1 (en) 2009-06-08 2009-06-08 MEANS ACTIVATING SEXUAL FUNCTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200900804A EA200900804A1 (en) 2009-06-08 2009-06-08 MEANS ACTIVATING SEXUAL FUNCTION

Publications (2)

Publication Number Publication Date
EA013948B1 EA013948B1 (en) 2010-08-30
EA200900804A1 true EA200900804A1 (en) 2010-08-30

Family

ID=42779161

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900804A EA200900804A1 (en) 2009-06-08 2009-06-08 MEANS ACTIVATING SEXUAL FUNCTION

Country Status (1)

Country Link
EA (1) EA200900804A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2507212C2 (en) * 2012-03-28 2014-02-20 Общество С Ограниченной Ответственностью "Айвикс" Method of producing recombinant peptide and obtained peptide
US10836794B2 (en) 2016-10-24 2020-11-17 “Ivix” Ltd. Group of peptides for treating female sexual dysfunction

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2404793C1 (en) 2009-06-04 2010-11-27 Общество с ограниченной ответственностью Био Пептид Stimulator of genital, sexual and reproductive function
RU2655763C2 (en) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Pharmaceutical composition and method for treating female sexual dysfunctions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2155065C1 (en) * 1999-04-23 2000-08-27 Институт молекулярной генетики РАН Anxiolytic agent and pharmaceutical composition with anxiolytic effect

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2507212C2 (en) * 2012-03-28 2014-02-20 Общество С Ограниченной Ответственностью "Айвикс" Method of producing recombinant peptide and obtained peptide
US9409947B2 (en) 2012-03-28 2016-08-09 “Ivix” Ltd. Method for producing a recombinant peptide and resultant peptide
US10836794B2 (en) 2016-10-24 2020-11-17 “Ivix” Ltd. Group of peptides for treating female sexual dysfunction

Also Published As

Publication number Publication date
EA013948B1 (en) 2010-08-30

Similar Documents

Publication Publication Date Title
AU2018260800B2 (en) Hepcidin analogues and uses therof
WO2012177444A3 (en) Glucagon/glp-1 receptor co-agonists
WO2012177443A3 (en) Glucagon/glp-1 receptor co-agonists
MX2013010376A (en) Stable formulations for parenteral injection of peptide drugs.
CR20130667A (en) COMPOSITIONS CONTAINING, METHODS THAT INVOLVED, AND USES DERIVED FROM DOLASTATIN UNITED TO NON-NATURAL AMINO ACIDS
MX2007009162A (en) Alcohol resistant dosage forms.
MX367850B (en) PREVENTION and TREATMENT OF INFLAMMATORY CONDITIONS.
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
EA200900804A1 (en) MEANS ACTIVATING SEXUAL FUNCTION
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PH12015502100A1 (en) Reducing the risk of autoimmune disease
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
WO2011156811A3 (en) Compounds for treatment of bovine mastitis
MX338405B (en) 2-iminobiotin formulations and uses thereof.
UA105552C2 (en) Plant extract for treating neurodegenerative diseases
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
EA201492238A1 (en) COMPOSITION MIZOPROSTOL
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
UA108865C2 (en) PARENTERAL PHARMACEUTICAL COMPOSITION IN THE VIEW OF THE SUSPENSION OF SUSTAINED RELEASE
WO2011133897A3 (en) Methods and materials for reducing liver fibrosis
HUP1600040A2 (en) Process for permanent aromatizing and increasing the nashing efficiency of soap nuts' shell, and compositions based on soap nut shell prepared by the process itself
WO2013117789A3 (en) Formylated xanthocillin analogues as neuroprotectants
EA201992040A1 (en) PERINATAL ADMINISTRATION OF SHORT-CHAIN FRUIT-LIGOSACCHARIDES FOR PREVENTION OF METABOLIC DISORDERS RELATED TO UNBALANCED NUTRITION AS AN ADULT
IN2013DE03119A (en)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment